NEWS
20231110
Seminar Takehiko Kaneko, CMO and Head of R&D at Heartseed, is speaking at Fierce Biotech Webinar on Nov. 28.
2023111
PR Heartseed Succeeds in Stable Production of High Purity Cardiomyocytes Using iPS Cells from I Peace, A Major Step Forward in Advancing Autologous Cardiac Regenerative Medicine
2023911
PR Heartseed Announces the Presentation of HS-001, an Investigational Stem Cell-Derived Therapy for the Treatment of Advanced Heart Failure at the 71st Annual Meeting of the Japanese College of Cardiology
202395
PR Heartseed Enters into induced Pluripotent Stem Cell Purification Patent License Agreement for Commercialization of Cell Therapy
202376
PR Heartseed Announces Positive 26-week Data for the First Patient in the Phase 1/2 Clinical Trial (LAPiS Study) Dosed With HS-001, an Investigational Stem Cell-Derived Therapy for the Treatment of Advanced Heart Failure
2023613
Media Heartseed selected as "Six companies that have made their name in the cardiovascular space" by LABIOTECH
2023525
PR Heartseed raises 2 billion JPY in series D funding to accelerate development of iPSC-derived stem cell therapy for heart failure
2023319
Media News article about the initiation of a clinical trial of Heartseed was published in Nature Medicine.